Thalys Medical Technology Group Inc. (603716.SS)
CNY 9.69
(-3.77%)
CNY 9.69
(-3.77%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -158.57 Million CNY | 17.09% |
| 2022 | -191.25 Million CNY | -398.36% |
| 2021 | -38.37 Million CNY | -146.78% |
| 2020 | 82.03 Million CNY | -25.71% |
| 2019 | 110.42 Million CNY | 17.27% |
| 2018 | 94.15 Million CNY | 0.33% |
| 2017 | 93.84 Million CNY | 36.17% |
| 2016 | 68.91 Million CNY | 12.14% |
| 2015 | 61.45 Million CNY | 8.74% |
| 2014 | 56.51 Million CNY | 15.19% |
| 2013 | 49.06 Million CNY | 28.0% |
| 2012 | 38.33 Million CNY | 1.45% |
| 2011 | 37.78 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -51.25 Million CNY | -546.37% |
| 2024 Q1 | 3.15 Million CNY | 102.04% |
| 2024 Q2 | -7.92 Million CNY | -351.18% |
| 2023 Q3 | -5.34 Million CNY | -132.52% |
| 2023 FY | -158.57 Million CNY | 17.09% |
| 2023 Q1 | -6.65 Million CNY | 96.8% |
| 2023 Q2 | 16.43 Million CNY | 347.14% |
| 2023 Q4 | -154.75 Million CNY | -2795.27% |
| 2022 Q2 | -12.8 Million CNY | -160.45% |
| 2022 Q1 | 21.18 Million CNY | 142.07% |
| 2022 FY | -191.25 Million CNY | -398.36% |
| 2022 Q4 | -207.73 Million CNY | -5956.03% |
| 2022 Q3 | 3.54 Million CNY | 127.7% |
| 2021 Q2 | -1.87 Million CNY | -136.53% |
| 2021 Q3 | -2.4 Million CNY | -28.05% |
| 2021 Q1 | 5.14 Million CNY | -82.23% |
| 2021 FY | -38.37 Million CNY | -146.78% |
| 2021 Q4 | -50.36 Million CNY | -1993.81% |
| 2020 Q2 | 32.73 Million CNY | 230.79% |
| 2020 Q1 | -25.03 Million CNY | -215.91% |
| 2020 FY | 82.03 Million CNY | -25.71% |
| 2020 Q4 | 28.93 Million CNY | 38.35% |
| 2020 Q3 | 20.91 Million CNY | -36.11% |
| 2019 Q2 | 34.68 Million CNY | 61.02% |
| 2019 FY | 110.42 Million CNY | 17.27% |
| 2019 Q3 | 32.43 Million CNY | -6.5% |
| 2019 Q4 | 21.59 Million CNY | -33.41% |
| 2019 Q1 | 21.54 Million CNY | -6.59% |
| 2018 Q3 | 22.8 Million CNY | -23.05% |
| 2018 Q2 | 29.63 Million CNY | 58.96% |
| 2018 Q1 | 18.64 Million CNY | -51.53% |
| 2018 FY | 94.15 Million CNY | 0.33% |
| 2018 Q4 | 23.06 Million CNY | 1.13% |
| 2017 Q4 | 38.46 Million CNY | 110.75% |
| 2017 Q3 | 18.25 Million CNY | -18.87% |
| 2017 Q2 | 22.49 Million CNY | 53.77% |
| 2017 Q1 | 14.63 Million CNY | -23.41% |
| 2017 FY | 93.84 Million CNY | 36.17% |
| 2016 Q3 | 19.67 Million CNY | -21.73% |
| 2016 FY | 68.91 Million CNY | 12.14% |
| 2016 Q4 | 19.1 Million CNY | -2.88% |
| 2016 Q2 | 25.13 Million CNY | 128.23% |
| 2016 Q1 | 11.01 Million CNY | -43.72% |
| 2015 Q4 | 19.56 Million CNY | 26.86% |
| 2015 FY | 61.45 Million CNY | 8.74% |
| 2015 Q3 | 15.42 Million CNY | 0.0% |
| 2014 FY | 56.51 Million CNY | 15.19% |
| 2013 FY | 49.06 Million CNY | 28.0% |
| 2012 FY | 38.33 Million CNY | 1.45% |
| 2011 FY | 37.78 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 273.29 Million CNY | 158.022% |
| Joinn Laboratories(China)Co.,Ltd. | 396.99 Million CNY | 139.943% |
| WuXi AppTec Co., Ltd. | 9.6 Billion CNY | 101.651% |
| Autobio Diagnostics Co., Ltd. | 1.21 Billion CNY | 113.025% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 643.38 Million CNY | 124.647% |
| Chemclin Diagnostics Co., Ltd. | 147.37 Million CNY | 207.598% |